Wall Street sell-side research analysts covering UnitedHealth Group Incorporated (NYSE:UNH) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $180.666 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $210 while the most conservative estimate stand at $145.
Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover UnitedHealth Group Incorporated. They give the company shares an ABR of 1.29. This is based on the 15 analysts taken into consideration by Zacks.
Earnings Estimates for UnitedHealth Group Incorporated (NYSE:UNH)
Currently, Wall Street is projecting that the firm will post $2.18 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-12-31, UnitedHealth Group Incorporated's EPS was reported as $2.11. This created a “surprise factor” 1.93% due to being $0.04 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.
Investors will mark their calendars for 2017-04-18, the date when UnitedHealth Group Incorporated (NYSE:UNH) are expected to release their quarterly results.
During the most recent trading session, Gilead Sciences, Inc. (NASDAQ:GILD) shares traded -0.21%. Tracking the stock price in relation to moving averages may provide enhanced perspective on stock performance. After a recent look, the stock has been seen trading $-1.79 off of the 50-day moving average of $68.75 and $-5.96 separated from the 200-day moving average of $72.92. Taking a further look from a different perspective, the stock has been recently recorded -35.05% off of the 52-week high of 103.10 and +2.42% apart from the 52-week low of 65.38. Monitoring stock price activity relative to moving averages and the highs and lows for the past year might help with future stock price value assessment.
Price Target in Focus
While monitoring stock technicals is important, most investors are more concerned with where the stock might be going now. Equity research analysts have provided views on where they believe the stock will be trading in the future. According to Thomson Reuters, sell-side analysts are projecting a consensus target price of $79.10 on company shares. This is a near-term estimate for the next 12-18 months.
Currently, Gilead Sciences, Inc. has a price to earnings ratio of 6.74. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The stock currently has a PEG Ratio of -1.69.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.